Ranibizumab for Neovascular Age-Related Macular Degeneration
Ranibizumab is administered as 0.5 mg intravitreal injections for neovascular AMD, starting with monthly injections until disease inactivity is achieved, then transitioning to individualized dosing regimens such as treat-and-extend or PRN (as-needed) protocols based on OCT and visual acuity monitoring. 1
Indication
Ranibizumab is indicated for neovascular (wet) AMD with choroidal neovascularization (CNV), including:
- Predominantly classic CNV
- Minimally classic CNV
- Occult CNV (with no classic lesions)
The goal is to prevent vision loss, improve visual acuity, and maintain quality of life by neutralizing all active forms of VEGF-A 2.
Dosing Regimens
Initial Loading Phase
Begin with monthly 0.5 mg intravitreal injections until disease becomes inactive (no subretinal/intraretinal fluid, no vision loss >5 letters, no new hemorrhage) 1, 3.
Maintenance Phase Options
The 2020 AAO Preferred Practice Pattern 1 recognizes three evidence-based approaches:
1. Fixed Monthly Dosing (Every 4 weeks)
- Provides maximum efficacy based on pivotal trials (MARINA, ANCHOR)
- Most intensive regimen with highest visit/injection burden
- Maintains initial visual gains most consistently
2. Treat-and-Extend Protocol (Preferred in clinical practice)
- After achieving disease inactivity, extend injection intervals by 2-week increments up to maximum 12 weeks 3
- If disease reactivates, shorten interval by 2 weeks
- Delivers comparable outcomes to monthly dosing: mean +8.0 letters at 24 months with average 5.6 injections in year 2 3
- This approach balances efficacy with reduced treatment burden 1
3. PRN (As-Needed) Dosing
- Inject only when disease activity detected on monthly monitoring
- Comparable 1-year efficacy to fixed dosing but does NOT maintain initial visual gains with longer follow-up 1
- Average 4.07 injections over 12 months 4
- Requires monthly monitoring visits, so treatment burden remains high despite fewer injections
Critical Dosing Caveat
The 0.3 mg dose showed efficacy in trials 2, but 0.5 mg is the standard clinical dose with superior outcomes (33.8% gained ≥15 letters vs 24.8% with 0.3 mg at 12 months) 2.
Monitoring Protocol
Disease Activity Assessment at Each Visit
Monitor with both OCT and visual acuity testing 1:
OCT findings indicating active disease:
- Subretinal fluid
- Intraretinal fluid (cystoid macular edema)
- Pigment epithelial detachment
- Increased central retinal thickness
Clinical findings indicating activity:
- Vision loss >5 letters from previous visit
- New or persistent retinal hemorrhage
Follow-up Schedule
- During active treatment: Monthly visits for assessment and injection decisions
- On treat-and-extend: Visits aligned with injection schedule (extending to maximum 12 weeks)
- After treatment discontinuation: Consider 3-month monitoring intervals in select patients with ≥3 consecutive visits showing complete inactivity at maximum interval 5
Expected Outcomes
Based on the landmark MARINA trial 2:
- 94.6% of patients lost <15 letters at 12 months (vs 62.2% sham)
- 33.8% gained ≥15 letters (vs 5.0% sham)
- Mean improvement of +7.2 letters maintained through 24 months
- However, real-world 5-year data shows only 50% maintain 20/40 vision 1
Safety Profile
Common complications to counsel patients about:
- Endophthalmitis: 1.0% over 24 months 2
- Serious uveitis: 1.3% over 24 months 2
- Retinal tears (rare)
- Theoretical systemic arterial thromboembolic events (clinical trial data inconclusive) 1
- Transient intraocular pressure elevation 1
Important safety notes:
- RPE tears may occur but are NOT a contraindication to continued therapy 1
- Avoid in pregnancy/lactation (risks unstudied) 1
- Recent literature review concluded anti-VEGF therapy is safe and effective for neovascular AMD 1
Common Pitfalls to Avoid
Undertreatment: Studies using variable dosing with mean 8.8 injections over 5 years showed moderate VA decrease and increased central retinal thickness 6. Maintain adequate injection frequency.
Premature treatment discontinuation: Only consider stopping after ≥3 consecutive visits at maximum interval showing complete disease inactivity 5. Patients with history of recurrence or only one good seeing eye should continue treatment.
Inadequate monitoring on PRN regimens: Disease activity can resurface between visits, leading to irreversible vision loss. Monthly monitoring is mandatory even when not injecting.
Ignoring OCT findings: Base retreatment decisions on objective OCT parameters (fluid), not just visual acuity, as structural changes precede functional decline 7.